SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai ($BBAI) is trending amid discussions about its acquisition of Ask Sage, an AI platform, and anticipation for the earnings call. The community is focused on the potential revenue from Ask Sage and its role in AI defense, with some hoping for significant stock movement soon. Recent after-hours momentum and AI sector strength may also be contributing to the increased attention.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending due to an after-hours tumble following its earnings report, despite a revenue beat; the company's lowered guidance is the primary concern, overshadowing positive metrics such as backlog growth. Community discussion revolves around whether this drop presents a buying opportunity or signals deeper issues, particularly related to revenue recognition and data center delays. Some traders believe the dip is an overreaction and a temporary setback for this AI infrastructure play.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as chatter increases around potential adoption by governments and its role in providing data to platforms like Kalshi. Community members are speculating on the potential impact of real-world asset (RWA) integration and comparing it to other cryptocurrencies.

Biggie is a popular Pitbull across several social media platforms, such as Tiktok, Youtube and Instagram. With a blend of creativity and comedic gestures, Biggie brings animal loving entertainment to millions of viewers through images, videos and reels. With Biggie the Pitbull's growing popularity, the meme coin $BIGGIE was inspired and launched on the ethereum network, leveraging Biggies unique sense of humor and style.

Biggie

Bigg has captured the attention of the crypto community, with many highlighting the influx of new traders and its trending status. Fueling the excitement are comparisons to other meme coins like Shiba Inu and Doge, with some suggesting BIGGIE has the potential for significant growth. Community members are encouraging each other to load up, emphasizing the potential for substantial returns.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as the community discusses the potential impact of a new CEO pay package and the upcoming R2 model launch. Bullish sentiment seems to be fueled by strong volume and the anticipation of Rivian's AI and Autonomy Day in December. Some investors are drawing parallels to Tesla's growth trajectory, while others remain cautious, citing profitability concerns.

UNI is the governance token for Uniswap, an Automated Market Marker DEX on the Ethereum blockchain. The UNI token allows token holders to participate in the governance of the protocol. Key decisions such as usage of the treasury or future upgrades can be decided through a governance vote.

UniSwap

Uniswap ($UNI) is trending as traders discuss its potential for significant gains and its strong technical setup. The community is actively watching for breakout opportunities and anticipating a potential surge, drawing comparisons to previous altcoin season patterns. Some users are pointing to the protocol's strong fundamentals, including substantial fee generation, as a reason for optimism.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending as investors discuss its recent delivery numbers and potential path to profitability, while also comparing its performance and strategy to competitors like Xpeng and Tesla. Community talking points include concerns about stock dilution and the effectiveness of NIO's battery swapping technology. The stock's movement relative to peers and the broader market seems to be fueling frustration and debate among investors.

Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.

Galecto Inc

Galecto Inc. ($GLTO) is trending due to its acquisition of Damora Therapeutics and a substantial funding round, leading to a massive surge in price and volume. Community discussions revolve around the potential for a multi-day run and a possible short squeeze, with some cautioning about potential pullbacks. The stock's low float and recent news are key factors driving the intense interest and volatility.

Bakkt Holdings, Inc. engages in the intersection of cryptoassets, loyalty and rewards, and payments. It also provides a platform to expand payment offerings, create new revenue streams, and increase customer loyalty. The company was founded in 2018 and is headquartered in New York, NY.

Bakkt Holdings Inc. - Ordinary Shares - Class A

Bakkt Holdings Inc

BKKT is trending due to recent price volatility and community discussions around earnings expectations, potential partnerships, and the impact of crypto market movements. Traders are actively discussing options strategies and the company's future prospects, with some expressing concerns about dilution and past performance. The addition of new board members and their potential influence is also a key talking point.

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

Anavex Life Sciences Corp

AVXL is trending amid anticipation for the CHMP opinion on its Alzheimer's drug, Blarcamesine, with a decision potentially arriving soon. Community discussions revolve around the likelihood of approval, the potential for a short squeeze, and speculation on future partnerships. Some believe approval is imminent due to the drug's safety profile and convenience compared to existing treatments, while others remain cautious, awaiting the official announcement.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tango Therapeutics, Inc. (TNGX) Tops Q3 Earnings and Revenue Estimates

Tango Therapeutics (TNGX) delivered earnings and revenue surprises of +1,200.00% and +23.20%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings Miss Estimates

Kiniksa Pharmaceuticals International, plc (KNSA) delivered earnings and revenue surprises of -30.30% and +8.91%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Take the Zacks Approach to Beat the Market: UnitedHealth, Ovid, Micron in Focus

Zacks' winning streak continues as UnitedHealth, Ovid and Micron deliver standout gains across key model portfolios.

XOMA Royalty Corporation (XOMA) and LAVA Therapeutics NV (LVTX) announced on Friday that they have agreed to amend their previous share purchase agreement and lowered the initial cash consideration to be received by LAVA shareholders.As per the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.xoma.com/news-events/press-releases/detail/487/xoma-royalty-and-lava-therapeutics-announce-amendment-to">amended deal</a>, LAVA shareholders will receive an initial cash payment of $1.04 per share, down from the range of $1.16 to $1.24 initially agreed upon. Shareholders will also receive a contingent value right (CVR) representing the right to certain cash payments, the companies said.This includes the previously announced rights to receive 75% of the net proceeds related to LAVA’s two partnered assets and 75% of any net proceeds from any out-license or sale of LAVA’s unpartnered programs, in addition to a new right to receive up to approximately $0.23 per CVR.LAVA and XOMA Royalty also agreed to amend LAVA’s minimum net-cash closing condition to be $24.5 million, compared to the previous minimum net-cash closing condition of $31.5 million. The amended agreement is in light of the most recent estimates of LAVA’s expected cash balance at closing, among other factors, the companies said. The proposed acquisition is expected to close in the fourth quarter of 2025, as announced previously.LAVA said that it expects to convene a meeting of shareholders to approve matters related to the deal with XOMA Royalty on November 7, after <a href="https://stocktwits.com/news-articles/markets/equity/lava-therapeutics-stock-drops-after-company-cancels-shareholder-meeting/chDD4XlR3BN">postponing</a> it from its previous date of September 30.Last month, LAVA canceled its shareholder meeting to consider and approve matters related to the proposed transaction with XOMA. XOMA first announced that it would acquire LAVA in August.<a href="https://stocktwits.com/symbol/LVTX">LAVA shares</a> fell 3% on Friday afternoon at the time of writing. On Stocktwits, retail sentiment around LVTX stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<figure class="image"><img style="aspect-ratio:588/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_17_at_2_25_55_PM_png_0c5aac6302.webp" alt="LVTX's Sentiment Meter and Message Volume as of 2:26 p.m. ET on Oct. 17, 2025 | Source: Stocktwits" width="588" height="63"><figcaption>LVTX's Sentiment Meter and Message Volume as of 2:26 p.m. ET on Oct. 17, 2025 | Source: Stocktwits</figcaption></figure>While LVTX shares have gained 56% this year, XOMA stock has risen 30%.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/kezar-life-sciences-stock-hit-with-downgrades-price-target-cuts/ch6sK5FR38U">Kezar Life Sciences Stock Hit With Downgrades And Price Target Cuts: Retail Keeps Hopes Alive</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

LAVA Therapeutics Stock Drops After Amended Deal With XOMA Royalty

As per the amended deal, LAVA shareholders will receive an initial cash payment of $1.04 per share, down from the range of $1.16 to $1.24 initially agreed upon.

Equity

As per the amended deal, LAVA shareholders will receive an initial cash payment of $1.04 per share, down from the range of $1.16 to $1.24 initially agreed upon.


Shares of LAVA Therapeutics (LVTX) declined 8% in the pre-market session on Tuesday after the company canceled the Extraordinary General Meeting of shareholders scheduled to occur today.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/30/3158434/0/en/LAVA-Therapeutics-to-Move-Extraordinary-General-Meeting-to-Early-November-2025.html">said</a> that it canceled the meeting to consider and approve certain matters related to its proposed transaction with XOMA Royalty Corporation (XOMA). XOMA announced in August that it will acquire LAVA for between $1.16 and $1.24 per share in cash, in addition to a contingent value right per share. The deal is expected to close in the fourth quarter (Q4) of 2025.The company said on Tuesday that it is canceling the meeting to continue discussions with XOMA concerning its estimated cash forecast and the consideration payable to the company’s shareholders in the transaction.LAVA also noted that both parties remain committed to completing the transaction by the fourth quarter.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LVTX">LVTX stock</a> rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.“We are committed to closing this transaction and look forward to working collaboratively with the LAVA team to further define LAVA’s cash forecast in an effort to close this transaction in an expeditious manner,” said XOMA CEO Owen Hughes.LAVA said on Tuesday that it expects to reconvene the shareholder meeting by early November. The date will be ascertained at a later date, and shareholders who have voted will have to cast their votes again on the matters proposed, it added.LVTX stock is up 69% this year but down approximately 3% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/chainlink-swift-advance-blockchain-integration-for-ubs-tokenized-funds/chDD4dRR3Bj">Chainlink, Swift Advance Blockchain Integration For UBS Tokenized Funds</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

LAVA Therapeutics Stock Slips 9% Pre-Market – Here’s Why The Company Canceled Its Shareholder Meeting

The firm stated it canceled the meeting to consider and approve certain matters related to its proposed transaction with XOMA Royalty Corporation. 

Does XOMA Royalty (XOMA) Have the Potential to Rally 85.34% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 85.3% in XOMA Royalty (XOMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict an 86.05% Upside in XOMA Royalty (XOMA): Here's  What You Should Know

The mean of analysts' price targets for XOMA Royalty (XOMA) points to an 86.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Here's Why XOMA Royalty (XOMA) Is a Great 'Buy the Bottom' Stock Now

After losing some value lately, a hammer chart pattern has been formed for XOMA Royalty (XOMA), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Mural Oncology PLC (MURA) and XOMA Royalty Corporation (XOMA) announced on Wednesday that they have entered into a definitive agreement under which a unit of XOMA will acquire Mural for cash.Under the <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.muraloncology.com/news-releases/news-release-details/mural-oncology-announces-entry-agreement-be-acquired-xra-5-corp">deal</a>, each Mural Shareholder would receive a cash price of between $2.035 and $2.24 per share. The base cash price represents a premium of approximately 13.1% to Mural’s closing share price of $1.80 on Tuesday. The additional price per share of up to $0.205 will be paid if Mural’s closing net cash exceeds estimates.MURA stock jumped 14% in the premarket session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MURA">Mural</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels. Meanwhile, retail sentiment around <a href="https://stocktwits.com/symbol/XOMA">XOMA</a> fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours.Mural's board of directors said that they have determined the acquisition and cash offer by XOMA, a biotechnology royalty aggregator, is in the best interest of all Mural shareholders. The board approved the acquisition and recommended that Mural shareholders vote in favor.The acquisition will be subject to the satisfaction of closing conditions, including approval by Mural shareholders. Excluding additional price per share, the deal values Mural at about $36.2 million.Mural Oncology announced plans to explore strategic alternatives in April after discontinuing all clinical development of Nemvaleukin. The decision followed data from a late-stage trial where Nemvaleukin in combination with Pembrolizumab did not achieve the primary endpoint of a statistically significant improvement in overall survival versus chemotherapy in platinum-resistant ovarian cancer. The company also saw no positive results from a mid-stage study of the drug in mucosal and cutaneous melanoma.MURA stock is down by 44% this year and over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-freezes-hiring-to-cut-costs-says-report/chsinAURdhO">Novo Nordisk Freezes Hiring To Cut Costs, Says Report: Retail Sees Stock Surpassing $100-Mark In A Year</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mural Oncology To Be Acquired By XOMA Royalty

The Mural board of directors said that they have determined the acquisition and cash offer by XOMA is in the best interest of all its shareholders. 

How Much Upside is Left in XOMA Royalty (XOMA)? Wall Street Analysts Think 106.15%

The average of price targets set by Wall Street analysts indicates a potential upside of 106.2% in XOMA Royalty (XOMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with various assets that provides right to future potential royalty and milestone payments. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.

XOMA Royalty Corp.

$NVDA

$MSFT

$AAPL

$GOOGL

Which of these Mag 7 stocks are you most bullish on right now?

XOMA
XOMA Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest XOMA News

XOMAXOMA Corp